Early RSV shot and wheezing in young children
Part of Lungs & breathing clinical trials.
This study looks at whether giving babies a shot called nirsevimab (which helps protect against RSV, a common virus that can cause breathing problems) early in life can reduce wheezing later on. It compares babies who got the shot with those who didn't.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby was born between February 6, 2023 and January 31, 2024.
- Your baby either received the nirsevimab shot before 6 or 12 months of age, or did not receive it at all.
- Your baby was not born in an overseas French territory (like Guadeloupe or Martinique).
- Your baby is not an identical twin (since they can't be told apart in the data).
- Your baby's mother did not get an RSV vaccine during pregnancy.
- Your baby did not receive another RSV drug called palivizumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
This study tests an RSV antibody shot that helps protect babies from severe RSV. It aims to see how well this preventive shot works in Aboriginal and Torres Strait Islander infants when given around 6-9 months of age.
This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.
This study follows babies under 12 months old who are hospitalized with bronchiolitis to understand their treatment and outcomes. It includes tracking RSV testing and a new immunization called nirsevimab, which may help protect against severe illness.
This study tests two approved ways to prevent RSV, a common virus that can make babies very sick. Pregnant women may get a vaccine, and/or their babies may get an antibody shot after birth. The study compares these options to see which works best.
Hear when a new Asthma Childhood trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.